Notice of Participation of the National Institute on Aging (NIA) in RFA-MH-19-510 "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)"

Notice Number: NOT-AG-18-029

Key Dates
Release Date: September 25, 2018

Related Announcements
 RFA-MH-19-510  

Issued by
National Institute on Aging (NIA)

Purpose

The purpose of this notice is to inform potential applicants that the National Institute on Aging (NIA) will participate, effective immediately, in the Funding Opportunity Announcement (FOA)
RFA-MH-19-510, "Novel Mechanism Research on Neuropsychiatric Symptoms (NPS) in Alzheimer's Dementia (R01 Clinical Trial Optional)".

The following sections have been updated to reflect the participation of NIA in this Funding Opportunity Announcement.

Part 1. Overview Information

The following information has been added:

Components of Participating Organizations:
National Institute on Aging (NIA)

Catalog of Federal Domestic Assistance (CFDA) Number(s):
93.866

 

Part 2. Section I. Funding Opportunity Description

Research Objectives:
The following information has been added:

In addition to the research areas listed, NIA is interested in the following lines of investigation:

  • Research that integrates epidemiologic, genomic and mechanistic research through the application of systems and network biology to understand the dynamic relationship between NPS and AD/ADRD pathogenesis across diverse populations.
  • Systems-based approaches aiming to examine the role of the gut-brain axis and the microbiome in the emergence of NPS in AD and as a mediator of the efficacy of interventions targeting NPS.
  • Research that aims to generate multi-omic data using biosamples from existing or legacy clinical trials targeting NPS in AD/ADRD (with pharmacologic and non-pharmacologic interventions) and apply a variety of computational approaches to interrogate disease mechanisms and to identify the molecular determinants of responsiveness to treatment. 
  • Research aimed at preclinical validation of candidate targets nominated by the AMP-AD Target Discovery and Preclinical Validation Consortium, to test their utility as therapeutic targets for NPS in AD/ADRD. A list of nominated targets can be accessed through the NIA-supported AGORA platform.

 

Academic-industry collaborations are strongly encouraged. 

Applicants are also encouraged to integrate across in silico and experimental approaches and across human, cell-based, and animal model studies.

Projects supported under this funding initiative should propose adequate annotation and curation of the molecular and clinical data types used and generated on the project to maximize the usability of the data by the broader research community for various types of meta-analyses and systems biology research.  

In keeping with NIA's strategic goal to enhance transparency of reporting and enable reproducible and translatable discovery research, applicants are expected to make all data, analytical methods and outputs, and research tools available to the broad scientific community prior to publication via the NIA-supported AMP-AD Knowledge Portal and/or related NIA/NIH designated data repositories. 

Part 2. Section II. Award Information

The following information has been added:

Funds Available and Anticipated Number of Awards
NIA intends to commit $4 million in total costs in fiscal year 2019 to support meritorious applications.

Part 2. Section VII. Agency Contacts

The following contacts have been added:

Scientific/Research Contact(s):
Suzana Petanceska, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-9350
Email: petanceskas@nia.nih.gov

Financial/Grants Management Contact(s):
Traci Lafferty
National Institute on Aging (NIA)
Telephone: 301-496-8987
Email: tracyi.lafferty@nih.gov

All other aspects of this FOA remain the same.

Inquiries

Please direct all inquiries to:

Suzana Petanceska, Ph.D.
National Institute on Aging (NIA)
Telephone: 301-496-9350
Email: petanceskas@nia.nih.gov